Table 3.
Different mRNA vaccines for different diseases which are registered for clinical trial.
| Vaccine targets | Clinical trials no. | Status (Phase) | Vaccine type | Sponsor/Organization |
|---|---|---|---|---|
| HIV−1 | NCT02888756 | Terminated (II) | Dendritic cell; loaded with viral antigenic mRNA with TriMix | Erasmus Medical Center |
| HIV−1 | NCT00833781 | Completed (II) | Dendritic cell loaded with viral antigenic mRNA | Massachusetts General Hospital |
| HIV−1 | NCT00381212 | Completed (I/II) | Dendritic cellelectroporated with autologous viral antigen and CD40L mRNAs | McGill University Health Centre |
| Zika Virus | NCT03014089 | Completed (I) | Nucleoside-modified viral antigenic mRNA | Moderna Therapeutics |
| Influenza | NCT03076385 | Completed (I) | ||
| HIV−1 | NCT02042248 | Completed (I) | Dendritic cellelectroporated with autologous viral antigen and CD40L mRNAs | ArgosTherapeutics |
| NCT00672191 | Completed (II) | |||
| NCT01069809 | Completed (II) | |||
| HIV−1 | NCT02413645 | Completed (I) | Viral Antigenic mRNA with TriMix | FundacióClínic per la Recerca Biomèdica |
| Rabies virus | NCT02241135 | Completed (I) | Viral antigenic mRNA (RNActive®) | CureVac AG |